Clinical scoring system for Sézary syndrome: results from a retrospective study

Clinical scoring system for Sézary syndrome: results from a retrospective study

VJHemOnc

1 year
47 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
An accurate and optimized clinical scoring system is essential for the staging and management of cutaneous T-cell lymphoma. Here, Pietro Quaglino, MD, of the University of Turin, Turin, Italy, discusses his group's retrospective study with a proposal for a scoring system for Sézary syndrome, in which particular features correlated with tumor burden and prognosis. This interview was recorded at the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland.
Up Next Autoplay
Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients
Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients
Category: Non-Hodgkin Lymphoma
1 Views
Cancer-News 1 day
Observations from PROVe Study #EORTC2019
Observations from PROVe Study #EORTC2019
Category: Non-Hodgkin Lymphoma
27 Views
Cancer-News 1 month
PROVe Study: How Long Are Patients On Therapy? #EORTC2019
PROVe Study: How Long Are Patients On Therapy? #EORTC2019
Category: Non-Hodgkin Lymphoma
14 Views
Cancer-News 1 month
PROVe study: Treatment of MF-CTCL Patients #EORTC2019
PROVe study: Treatment of MF-CTCL Patients #EORTC2019
Category: Non-Hodgkin Lymphoma
20 Views
Cancer-News 1 month
Verastem Oncology Receives Orphan Drug Designation from FDA for COPIKTRA for the Treatment of T-Cell Lymphoma
Verastem Oncology Receives Orphan Drug Designation from FDA for COPIKTRA for the Treatment of T-Cell Lymphoma
Category: Non-Hodgkin Lymphoma
14 Views
Cancer-News 1 month
CLL and Non-Hodgkin Lymphoma, What new drugs are on the horizon and why are they exciting
CLL and Non-Hodgkin Lymphoma, What new drugs are on the horizon and why are they exciting
Category: Non-Hodgkin Lymphoma
231 Views
cancergrace 4 months
CLL and Non-Hodgkin Lymphoma, What are the risks and benefits of both ibrutinib and Idelalisib
CLL and Non-Hodgkin Lymphoma, What are the risks and benefits of both ibrutinib and Idelalisib
Category: Non-Hodgkin Lymphoma
125 Views
cancergrace 4 months
Chronic Lymphocytic Leukemia,  Non-Hodgkin Lymphoma, Should all HL patients be treated the same
Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, Should all HL patients be treated the same
Category: Non-Hodgkin Lymphoma
115 Views
cancergrace 4 months
The Clinical Study Investigating Mosunetuzumab
The Clinical Study Investigating Mosunetuzumab
Category: Non-Hodgkin Lymphoma
111 Views
obr 10 months
Results Of The AUGMENT Study In Relapsed/Refractory Indolent NHL
Results Of The AUGMENT Study In Relapsed/Refractory Indolent NHL
Category: Non-Hodgkin Lymphoma
47 Views
obr 10 months